10/16/2019
Cleveland Diagnostics Announces FDA Breakthrough Device Designation for Novel Prostate Cancer Diagnostic Test
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the early detection of cancers, announced today that it has received FDA Breakthrough Device Designation for the IsoPSA® Assay, a novel prostate cancer diagnostic test. Published studies from multicenter prospective clinical trials suggest that the non-invasive, blood-based IsoPSA assay has significant superior diagnostic accuracy when compared to traditional prostate-specific antigen (PSA) tests in detecting high-grade prostate cancer.
06/20/2019
Xealth adds Atrium Health, Cleveland Clinic and MemorialCare to close $14m Series A
Xealth, the leading platform for connecting digital health, today announced that it has secured an additional $3 million in its Series A financing, bringing the amount raised in this round to $14 million total. New investors Atrium Health, Cleveland Clinic and MemorialCare Innovation Fund join McKesson Ventures, Novartis, Philips, ResMed, Threshold Ventures (formerly DFJ Venture), Providence Ventures, UPMC and Froedtert and the Medical College of Wisconsin health network. Investments from this round will be used to advance the development and deployment of the Xealth platform for digital health programs.
05/30/2019
Catapult, Prevent Biometrics Partner to Sync Safety, Performance Data
In conducting extensive trials with college and high school sports teams, Prevent Biometrics found value in syncing the impact data gleaned from its smart mouthguards with game video to provide context on collisions.
05/07/2019
Cleveland Diagnostics Announces Publication of Multicenter IsoPSA Clinical Validation Study Demonstrating Improved Accuracy Over Prostate-Specific Antigen Test
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online publication of results from a multicenter validation study of IsoPSA™, a novel structure-based prostate cancer assay, in Journal of Urology. The study validated the findings from a preliminary study published earlier in European Urology, demonstrating that the non-invasive, blood-based IsoPSA assay has superior diagnostic accuracy over the current gold standard, prostate-specific antigen (PSA), in detecting high-grade prostate cancer.
04/23/2019
Cleveland Clinic spinoff company to start clinical trials for Alzheimer's disease
Cleveland Clinic spinoff company NeuroTherapia Inc. will start clinical trials of a new drug targeting inflammation of the brain that's found in Alzheimer's and other neurological diseases, according to a news release.
04/04/2019
Shivom Partners With Cleveland Clinic Spinout Family Care Path
Shivom announced today that it has signed an agreement to offer Family Care Path's MyLegacy web-based clinical decision support application to its customers.
01/30/2019
GCV Rising Stars Awards 2019: Jack Miner
Jack Miner leads Cleveland Clinic Ventures, a team of venture experts charged with funding the full lifecycle – from product-development company to exit – at the US-based healthcare services provider.
01/02/2019
Astellas Executes License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas
Developed through research at Cleveland Clinic, Juventas Therapeutics, the clinical stage biotechnology company, is a pioneer in non-viral gene therapies. Licensed and spun-out through Cleveland Clinic Innovations, Juventas raised more than $50 million to advance its primary gene therapy candidate JVS-100, from concept through Phase II clinical studies in heart failure and Peripheral Artery Disease (PAD).
12/12/2018
Subscribe From Subaru Ascent to Apple Watch Series 4: The biggest product launches of 2018
This year, American consumer confidence hit a near 18-year high. These conditions – which often translate to increased consumer spending – provide an ideal environment for companies to introduce innovative new products. Prevent Biometrics is listed at #5.
10/22/2018
Prevent Biometrics® Acquires Assets of X2 Biosystems, Consolidating Leadership in Head Impact Monitoring
Prevent Biometrics, the Cleveland Clinic spinoff that developed the first accurate, real-time system for monitoring head impacts in contact sports, today announced that it has acquired the head impact monitoring assets of Seattle-based X2 Biosystems. The transaction brings together the two leading head impact monitoring technologies, Prevent’s Impact Monitor Mouthguard, and X2’s skin patch-based platform.